Post-marketing safety surveillance conducted in Korea (2008–2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)

References

• Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6; PMID:16494759; http://dx.doi.org/10.3201/eid1202.050006
   PubMed Web of Science ®Google Scholar
• CDC. Reduction in rotavirus after vaccine introduction—United States, 2000–2009. MMWR 2009; 58:1146-9; PMID:19847149
   PubMedGoogle Scholar
• Orenstein EW, Fang ZY, Xu J, Liu C, Shen K, Qian Y, Jiang B, Kilgore PE, Glass RI. The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine 2007; 25:406-13; PMID:16956700; http://dx.doi.org/10.1016/j.vaccine.2006.07.054
   PubMed Web of Science ®Google Scholar
• Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011; 365:772-3; PMID:21864191; http://dx.doi.org/10.1056/NEJMc1100062
   PubMed Web of Science ®Google Scholar
• Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006; 134:908-16; PMID:16650331; http://dx.doi.org/10.1017/S0950268806006091
   PubMed Web of Science ®Google Scholar
• Korea Centers for Disease Control and Prevention. Molecular epidemiology of group A rotavirus infection in Korea. Public Health Weekly Report 2008; 20:325-8
   Google Scholar
• Kang JO, Kim MN, Kim J, Suh HS, Yoon Y, Jang S, Chang C, Choi S, Nyambat B, Kilgore PE. Epidemiologic trends of rotavirus infection in the Republic of Korea, July 1999 through June 2002. Ann Lab Med 2002; 23:382-387
   Google Scholar
• Seo JK, Sim JG. Overview of rotavirus infections in Korea. Pediatr Int 2000; 42:406-10; PMID:10986878; http://dx.doi.org/10.1046/j.1442-200x.2000.01250.x
   PubMed Web of Science ®Google Scholar
• Kim JS, Kang JO, Cho SC, Jang YT, Min SA, Park TH, Nyambat B, Jo DS, Gentsch J, Bresee JS, et al. Epidemiological profile of rotavirus infection in the Republic of Korea: results from prospective surveillance in the Jeongeub District, 1 July 2002 through 30 June 2004. J Infect Dis 2005; 192:S49-56; PMID:16088805; http://dx.doi.org/10.1086/431506
   PubMed Web of Science ®Google Scholar
• Kim MJ, Jeong HS, Kim SG, Lee SM, Kim SH, Kee HY, Jo EH, Park HJ, Ha DR, Kim ES, et al. Diversity of Rotavirus strains circulated in Gwangju, Republic of Korea. Osong Public health and research perspectives 2014; 5(6):364-9; PMID:25562046; http://dx.doi.org/10.1016/j.phrp.2014.10.004
   PubMedGoogle Scholar
• Kim DS, Lee TJ, Kang JH, Kim JH, Lee JH, Ma SH, Kim SY, Kim HM, Shin SM. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008; 27:177-8; PMID:18174862; http://dx.doi.org/10.1097/INF.0b013e31817d877a
   PubMed Web of Science ®Google Scholar
• Kim JS, Bae CW, Lee KY, Park MS, Choi YY, Kim KN, Kim JD, Park WS, Sin JB, Kim EA, et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Hum Vaccine Immunother 2012; 8:806-12; http://dx.doi.org/10.4161/hv.19853
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Human Rotavirus Vaccine Study Group. Safety and effi¬cacy of an attenuated vaccine against severe rotavi¬rus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30:A44-51; PMID:22520136; http://dx.doi.org/10.1016/j.vaccine.2011.08.080
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63; PMID:18037080; http://dx.doi.org/10.1016/S0140-6736(07)61744-9
   PubMed Web of Science ®Google Scholar
• Shim JO, Than VT, Ryoo E, Lim I, Yoon Y, Kim K, Chung SI, Kim W. Distribution of Rotavirus G and P Genotypes Approximately Two Years Following the Introduction of Rotavirus Vaccines in South Korea. J Med Virol 2013; 85:1307-12; PMID:23595867; http://dx.doi.org/10.1002/jmv.23586
   PubMed Web of Science ®Google Scholar
• Choi UY, Lee SY, Ma SH, Jang YT, Kim JY, Kim HM, Kim JH, Kim DS, Kim YS, Kang JH. Epidemiological changes in rotavirus gastroenteritis in children under 5 years of age after the introduction of rotavirus vaccines in Korea. Eur J Pediatr 2013; 172:947-52; PMID:23443155; http://dx.doi.org/10.1007/s00431-013-1974-y
   PubMed Web of Science ®Google Scholar
• Bravo L, Chitraka A, Liu A, Choudhury J, Kumar K, Berezo L, Cimafranca L, Chatterjee P, Garg P, Siriwardene P, et al. Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. Hum Vaccin Immunother 2014; 10(8):2276-83; PMID:25424932; http://dx.doi.org/10.4161/hv.29280
   PubMed Web of Science ®Google Scholar
• Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta SK, Suryakiran PV, Delem A, Han HH, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 2009; 5:414-9; PMID:19276664; http://dx.doi.org/10.4161/hv.5.6.8176
   PubMed Web of Science ®Google Scholar
• Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T. The human rotavi¬rus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatr Infect Dis J 2009; 28:225-32; PMID:19209095; http://dx.doi.org/10.1097/INF.0b013e31819715fa
   PubMed Web of Science ®Google Scholar
• Buyse H, Vinals C, Karkada N, Han H. The human rotavirus vaccine Rotarix™ in infants. An integrated analysis of safety and reactogenicity. Hum Vaccin Immunother 2014; 10(1):19-24; PMID:24047799; http://dx.doi.org/10.4161/hv.26476
   PubMed Web of Science ®Google Scholar
• Rotarix Korean Prescribing Information. Available at: https://www.gsk-korea.co.kr/upload/product/rotarix_20160318[1].pdf [accessed on 29 Mar, 2016] [In Korean]
   Google Scholar
• Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine 2011; 29(11):2079-84; PMID:21238572; http://dx.doi.org/10.1016/j.vaccine.2011.01.004
   PubMed Web of Science ®Google Scholar
• Dokgo YC. Vaccination Guideline. 5 ed. Seocho World Office, Seo Cho-dong Seo Cho-Gu Seoul Korea: Korea Society of Pediatrics 2002.
   Google Scholar
• Adverse Reaction Terminology WHO-ART. Uppsala (Sweden): The Uppsala Monitoring Center. Available at: http://www.umc-products.com/graphics/28010.pdf [Accessed on 29 Mar 2016]
   Google Scholar